Database/Guides/GLOW Stack (GHK-Cu + BPC-157 + TB-500)
Healing & Repair

GLOW Stack (GHK-Cu + BPC-157 + TB-500)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Orthopedic, Regenerative & Aesthetic Applications

📋 Full Clinical Guide⬇ Download Guide🧮 Calculator
Dosing Reference
70mg vialSubQ · Hair/Skin/Collagen
BAC Water
2mL
Amt / Unit
0.35mg/unit
Dose Range
3.5-7mg
Draw (units)
10-20 units
Frequency
Daily x 20 days
Route
SubQ
ℹSkin, longevity, healing combo. 3x annually
Clinical Use Cases
skin rejuvenationanti-agingcollagen supporthealinglongevity
Clinical Guide
Open full guide →
Important Notice: GHK-Cu, BPC-157, and TB-500 are not FDA-approved drugs. All uses constitute off-label, investigational, and experimental use and must comply with all applicable federal/state regulations, medical board rules, and institutional policies. This document is educational only and does not constitute medical advice or establish a standard of care.

1. Clinical Overview of the GLOW Stack

1.1 Components

GHK-Cu (Glycyl-L-histidyl-L-lysine–Copper)

Endogenous copper tripeptide. Levels decline with age. Stimulates collagen I/III, elastin, GAGs, regulates MMPs/TIMPs, supports wound healing, angiogenesis, anti-inflammatory/antioxidant pathways, and beneficial gene expression patterns.

BPC-157 (Body Protection Compound-157)

Cytoprotective gastric pentadecapeptide. Strong angiogenic, endothelial-protective, GI-healing, and tendon/ligament restorative effects.

TB-500 (Thymosin Beta-4 Fragment)

Regulates actin dynamics, cell migration, angiogenesis, and wound repair, reduces fibrosis and adhesions.

Together, these three create a dermo-regenerative + structural repair stack: GHK-Cu remodels and upgrades the extracellular matrix, while BPC-157 and TB-500 provide deep angiogenic, cytoskeletal, and tendon/ligament support.

1.2 Primary Clinical Domains of Interest

  • Aesthetic Dermal Remodeling: Photoaging, fine lines, texture, early laxity; post-microneedling/RF/laser recovery; scar modulation
  • Hair & Scalp: Adjunct in hair density and follicle-support protocols
  • Soft-Tissue & Orthopedic Adjunct: Tendon, ligament, fascia, muscle support when aesthetic priorities coexist with structural injuries

2. Mechanisms of Action & Synergy Model

2.1 GHK-Cu — Key Mechanistic Domains

  • ECM Remodeling & Collagen/Elastin Synthesis
  • MMP/TIMP Modulation & Scar Remodeling
  • Angiogenesis & Microcirculation
  • Anti-Inflammatory & Antioxidant Effects
  • Gene Expression Reprogramming (>4,000 repair genes)

2.2 BPC-157 — Key Mechanistic Domains

  • Angiogenesis & Endothelial Repair
  • GI mucosal and barrier protection
  • Tendon-to-bone interface healing and collagen organization
  • Neurovascular and endothelial-stabilizing effects

2.3 TB-500 — Key Mechanistic Domains

  • Actin sequestration and enhanced cell migration
  • Strong angiogenic signaling (VEGF-related)
  • Anti-fibrotic and anti-adhesion effects
  • Improved collagen orientation and tensile strength

2.4 GLOW Stack Synergy

DomainGHK-CuBPC-157TB-500Net Effect
Dermal ECM Remodeling↑ Collagen, elastin, GAGs; MMP/TIMPIndirect via angiogenesisWound closure & ECM alignmentHigh-yield dermal rejuvenation
AngiogenesisPotent microvascular modulationOrganized microvascular repairStrong VEGF-mediatedRobust but ordered perfusion
Scar & AdhesionECM turnover, decorin, gene shiftsAnti-inflammatory & tissue repairAnti-fibrotic, reduces adhesionsImproved scar quality
Tendon/LigamentSupportive via ECM & microvesselsDirect tendon/ligament healingCollagen alignment & migrationStructural + cosmetic improvement
Anti-inflammatoryNF-κB, cytokine, antioxidantEndothelial & NO modulationAnti-inflammatoryLower chronic inflammatory burden

3. GLOW Stack Product Specifications

Per Vial (Lyophilized Blend): 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 = 70 mg total peptide content

Positioning: Aesthetic-first, with structural and orthopedic support as a bonus.

Synergy with Oral RECOVER™: RECOVER™ contains BPC-157 (500 mcg) + GHK-Cu (2 mg) + Carnosine (500 mg) in a staged-release capsule, forming a systemic backbone while GLOW provides local, concentrated field dosing.

4. Reconstitution & Dosing Frameworks

4.1 General Principles

  • Diluent: Bacteriostatic 0.9% saline per clinic SOP
  • Strict aseptic technique
  • Refrigerate reconstituted vials (often 7–14 days)
  • Use 1 mL insulin syringes for accurate mesotherapy micro-dosing

Vial ratio: GHK-Cu : BPC-157 : TB-500 = 50 : 10 : 10 (5:1:1). Whatever total mg/mL you choose, that ratio holds.

Option A — "Balanced Field" Concentration (10 mL total)

Add 10 mL bacteriostatic saline → GHK-Cu 5 mg/mL · BPC-157 1 mg/mL · TB-500 1 mg/mL · Total 7 mg/mL

Dose Mapping: 0.10 mL → 0.5 mg GHK-Cu + 0.1 mg each BPC/TB · 0.20 mL → 1.0 mg + 0.2 mg each · 0.50 mL → 2.5 mg + 0.5 mg each

Best For: Facial/neck mesotherapy grids, scar fields, scalp applications

Option B — "High-Impact Aesthetic" Concentration (5 mL total)

Add 5 mL bacteriostatic saline → GHK-Cu 10 mg/mL · BPC-157 2 mg/mL · TB-500 2 mg/mL · Total 14 mg/mL

Dose Mapping: 0.05 mL → 0.5 mg GHK-Cu + 0.1 mg each · 0.10 mL → 1.0 mg + 0.2 mg each · 0.20 mL → 2.0 mg + 0.4 mg each

Best For: Smaller high-value fields (periorbital, perioral, focal scars), minimizing injection volume

Option C — "Wide-Field / Sensitive Skin" Concentration (20 mL total)

Add 20 mL bacteriostatic saline → GHK-Cu 2.5 mg/mL · BPC-157 0.5 mg/mL · TB-500 0.5 mg/mL · Total 3.5 mg/mL

Dose Mapping: 0.10 mL → 0.25 mg GHK-Cu + 0.05 mg each · 0.20 mL → 0.5 mg + 0.1 mg each · 0.50 mL → 1.25 mg + 0.25 mg each

Best For: Highly sensitive skin, very wide treatment areas, cautious clinics

4.4 Session-Level Dose Ranges

Small focal area (scar, peri-ocular): ~1–2 mg GHK-Cu (+ 0.2–0.4 mg BPC-157 + 0.2–0.4 mg TB-500)
Full face or neck: ~3–5 mg GHK-Cu total (BPC/TB proportionally 0.6–1 mg each)
Full face + neck + décolletage: ~5–8 mg GHK-Cu (advanced clinics)
Frequency: Every 4 weeks (device-based) or every 2–4 weeks (injection-only) · Series: 3–6 sessions

5. Route Selection & Injection Strategies

5.1 Primary Routes

  • Intradermal / Mesotherapy-Style Grids: 1–3 mm depth, 0.02–0.10 mL per micro-depot, ~1–1.5 cm spacing
  • Superficial Subcutaneous / Subdermal: For thicker dermis/fat or scars, 0.05–0.20 mL per point
  • Peri-scar / Peri-fascial / Peri-tendinous: Combined structural + aesthetic work

No intra-articular use is recommended or endorsed for this aesthetic-focused blend.

5.2 Example Injection Patterns

A. Facial Rejuvenation — Full Face Mesotherapy

5–10 mg/mL GHK-Cu, 1–1.5 cm grid, 0.03–0.05 mL per point, ~3–5 mg GHK-Cu/session

B. Focal Scar (post-surgical linear scar)

5–10 mg/mL GHK-Cu, intradermal/SC along scar + fanning, 0.05–0.1 mL every 5–10 mm, ~1–3 mg/session

C. Neck & Décolletage Laxity + Texture

2.5–5 mg/mL, broad grid at 1–1.5 cm, ~3–6 mg GHK-Cu per combined session

D. Scalp Support (Adjunct in Hair Protocols)

5–10 mg/mL GHK-Cu, micro-depots in thinning zones, 0.02–0.05 mL per point, ~2–4 mg/session

6. Integration with Oral RECOVER™ and Other Peptide Protocol Portal Products

6.1 Oral RECOVER™ as Systemic Backbone

RECOVER™ = BPC-157 500 mcg + GHK-Cu 2 mg + Carnosine 500 mg, staged-release.
Protocol: 1 capsule each morning on empty stomach · 5 days on / 2 days off · 8–12 weeks

6.2 Why Combine RECOVER™ with GLOW?

  • Systemic ECM & microvascular support from RECOVER™
  • Local high-concentration dermal + structural support from GLOW
  • Combined BPC-157 + GHK-Cu supports dermal remodeling, angiogenesis, GI/endothelial resilience, and post-procedure recovery
Caution: Total copper exposure rises when combining RECOVER™ + GLOW + topical GHK-Cu. Use heightened caution in patients with copper metabolism disorders, advanced liver disease, or complex chelation regimens.

6.3 Combined Protocol Examples

Aesthetic Series (Microneedling + GLOW + RECOVER™)

RECOVER™ 1 cap AM, 5/2 cycling × 12 wks · Microneedling q4 wks × 4 sessions · GLOW intradermal at each session · Topical GHK-Cu serum home care

Scar Remodeling

RECOVER™ 1 cap AM × 12–16 wks · GLOW peri-scar injections q4 wks × 3–6 sessions · Optional PRiVIVE™ post-needling/subcision

7. Clinical Decision Trees

7.1 Decision Tree 1 — Is GLOW the Right Stack?

1. Primary goal aesthetic (skin, scar, scalp) ± structural? → Yes → Consider GLOW

2. Opportunity to combine with procedures (microneedling, RF, laser, PRP/PRF)? → Yes → GLOW well-suited as peri-procedural adjunct

3. Copper-related risks (Wilson disease, hepatic impairment)? → Yes → Avoid or use non-copper protocols

4. Patient committed to multi-session series? → Yes → Build 3–6 session GLOW + procedure plan

Not committed? → Prioritize 1–2 key interventions; topical + oral only

7.2 Decision Tree 2 — Route & Concentration Selection

Step 1 — Field Size & Sensitivity: Small focal → Option B (higher conc.) · Large/sensitive → Option C (lower conc.)

Step 2 — Procedure Intensity: Deep/aggressive resurfacing → delay GLOW until re-epithelialization · Mild microneedling/RF → GLOW immediately or within 24–72 hrs

Step 3 — Structural Component: Significant tendon/ligament involvement → slightly deeper SC/peri-fascial micro-depots; consider Wolverine Blend for separate structural sessions

8. Example Clinical Archetypes

Archetype A — Full-Face Rejuvenation Series

Systemic: RECOVER™ 1 cap AM, 5-on/2-off for 12 weeks

Local GLOW (Option A: 5 mg/mL GHK-Cu): ~4 mg GHK-Cu/session, 0.03–0.05 mL per point, full face grid, q4 weeks × 4 sessions

Adjuncts: Microneedling or RF each visit · Daily topical GHK-Cu serum at home

Archetype B — Focal Surgical Scar (e.g., abdominoplasty, C-section)

Systemic: RECOVER™ 1 cap AM × 12–16 weeks

Local GLOW (Option B: 10 mg/mL GHK-Cu): 2–3 mg GHK-Cu/session, 0.05–0.1 mL intradermal/SC along scar q10–15 mm, q4 weeks × 3–6 sessions

Adjuncts: Scar massage, silicone sheeting, sun protection

Archetype C — Scalp Support with PRP

Systemic: RECOVER™ 1 cap AM × 12 weeks

Procedural: PRP scalp injections q4–6 weeks × 3–4 sessions

Local GLOW (Option A or B): ~2–4 mg GHK-Cu/session, mesotherapy micro-depots across thinning zones after PRP

Archetype D — Hybrid Aesthetic + Shoulder Scar/Soft-Tissue Support

Systemic: RECOVER™ 1 cap AM ± REBALANCE™ PM for sleep/ANS support

Local: Face: GLOW mesotherapy q4–6 wks · Shoulder scar: GLOW peri-scar injections q4–6 wks · Deeper tendon pathology: separate Wolverine Blend sessions

9. Safety, Contraindications & Monitoring

9.1 Safety Overview

GHK-Cu is an endogenous peptide with a generally favorable tolerability profile, yet higher-dose injectable use is less well characterized and remains investigational. Combining with BPC-157 and TB-500 increases mechanistic complexity; conservative dosing, careful patient selection, and robust informed consent are critical.

9.2 Contraindications

Absolute

  • Pregnancy
  • Lactation
  • Known hypersensitivity to any component
  • Inability to provide informed consent

Relative / Use With Caution

  • Copper metabolism disorders (e.g., Wilson disease)
  • Significant hepatic impairment
  • Chelation therapy or complex metal-regulating regimens
  • Coagulation disorders or potent anticoagulation (injectable routes)
  • Active infection at injection sites

9.3 Monitoring

Subjective: Skin tolerance, perceived skin quality/scar changes, GI tolerance with RECOVER™

Objective: High-resolution photography, scar scales (e.g., Vancouver Scar Scale), LFTs and copper/ceruloplasmin labs in high-risk protocols

Potential Adverse Effects: Injection-site discomfort/bruises/nodules, short-lived erythema/edema, theoretical copper overload with aggressive combined regimens.

Legal & Regulatory Notice

The information contained in this GLOW Stack Clinical Protocol Guide is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

GHK-Cu, BPC-157, and TB-500, individually or in combination as the GLOW Stack, are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — GLOW Stack Clinical Reference Guide

GHK-Cu (Copper Tripeptide-1) — Foundational Biology, ECM Remodeling & Aesthetic Applications
1. Pickart, L. The human tripeptide GHK and tissue remodeling. J Biomater Sci Polym Ed, 19(8), 969–988 (2008).
2. Pickart, L., & Margolina, A. GHK peptide as a natural modulator of gene expression. Biomed Res Int, 2015, 648108 (2015).
3. Maquart, F. X., et al. Stimulation of collagen synthesis by GHK-Cu in fibroblasts. FEBS Lett, 238(2), 343–346 (1988).
4. Simeon, A., et al. GHK-Cu increases decorin and angiogenesis-related factors. J Cell Physiol, 177(1), 1–9 (1998).
5. Pollard, H. B., et al. GHK-Cu as a regulator of >4,000 genes involved in repair. Physiol Genomics, 44(24), 1198–1206 (2012).
6. Al Tuwaijri, A. A., et al. Topical GHK-Cu improves photoaging and reduces wrinkles. Dermatol Surg, 22(4), 347–351 (1996).
7. Ahmed, M. I., et al. GHK-Cu enhances hair follicle enlargement and growth. J Dermatolog Treat, 24(3), 171–178 (2013).
8. Godin, M. S., et al. Copper tripeptide complex improves wound healing and reduces scarring. Aesthetic Surg J, 14(2), 94–104 (1994).
9. Arul, V., et al. GHK-Cu accelerates healing in ischemic and diabetic wound models. J Surg Res, 178(1), 79–87 (2012).
BPC-157 — Cytoprotection, Angiogenesis, Tendon/Ligament Healing & Endothelial Repair
10. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. Stable gastric pentadecapeptide BPC-157: Multi-organ healing effects. Curr Pharm Des, 24(19), 2182–2200 (2018).
11. Sikiric, P., Seiwerth, S., Pavlovic, V., et al. Angiogenic and cytoprotective properties of BPC-157. J Physiol, 596(6), 965–982 (2018).
12. Staresinic, M., et al. BPC-157 accelerates wound healing and reduces adhesion formation. Dig Dis Sci, 48(10), 2072–2080 (2003).
13. Seiwerth, S., et al. Tendon and ligament healing acceleration with BPC-157. J Orthop Res, 32(5), 683–691 (2014).
14. Novak, M., et al. BPC-157 improves recovery of muscle, tendon, ligament, and bone. Acta Orthop Belg, 66(1), 53–60 (2000).
15. Gojkovic, S., et al. BPC-157 counteracts NSAID-induced GI damage. Life Sci, 173, 32–40 (2017).
16. Sikiric, P., Rucman, R., et al. GI barrier restoration & inflammation reduction with BPC-157. Inflamm Res, 59(11), 921–930 (2010).
17. Seiwerth, S., et al. Endothelial protection and microvascular repair via BPC-157. Vasc Pharmacol, 102, 1–9 (2018).
18. Jelovac, T., et al. BPC-157 promotes neurological and peripheral nerve repair. Neurosci Lett, 587, 13–18 (2015).
19. Vukojević, J., et al. Multi-tissue healing properties of BPC-157. Int J Mol Sci, 20(19), 4957 (2019).
TB-500 (Thymosin Beta-4 Fragment) — Cell Migration, Actin Modulation, Angiogenesis & Anti-Fibrotic Activity
20. Low, T. L. K., & Goldstein, A. L. Discovery and characterization of Thymosin Beta-4. PNAS, 72(1), 200–204 (1975).
21. Huff, T., et al. Structure–function overview of Thymosin Beta-4. Ann N Y Acad Sci, 1112, 402–414 (2007).
22. Safer, D., et al. Interaction of Tβ4 with actin and cytoskeletal regulation. PNAS, 88(14), 6608–6612 (1991).
23. Sosne, G., et al. Identification of active wound-healing fragments (TB-500 region). J Biol Chem, 279(7), 5389–5396 (2004).
24. Smart, N., et al. Peptide fragments of Thymosin β4 stimulate tissue regeneration. Nature, 474(7351), 444–448 (2011).
25. Malinda, K. M., et al. Tβ4 enhances keratinocyte migration and wound closure. J Invest Dermatol, 113(1), 112–120 (1999).
26. Sosne, G., et al. Anti-inflammatory and reparative effects of Tβ4 fragments. Invest Ophthalmol Vis Sci, 43(3), 756–762 (2002).
27. Yang, H., et al. TB-500 suppresses TGF-β–mediated fibrosis and adhesion formation. Cell Physiol Biochem, 31(1), 67–78 (2013).
28. Bock-Moloney, M. C., et al. Preclinical systemic safety of Thymosin peptides. Toxicol Pathol, 39(7), 1101–1112 (2011).
🔒

Provider Access Required

Create a provider account to read the full clinical guide for GLOW Stack (GHK-Cu + BPC-157 + TB-500).

Quick Links